Cognitive decline tracking company Neurotrack has raised $9.9 million in a new round of equity financing, according to an SEC filing posted this week.
Palo Alto, Calif.-based Neurotrack’s 1st product is the Imprint, a digital cognitive assessment test designed to track cognitive decline and help advance research and treatment of cognitive diseases like Alzheimers.
The test utilizes eye tracking technology to assess recognition memory and hippocampal impairment, the company said, and is built on more than 30 years of research led by its co-founder Dr. Stuart Zola.
The company said that the funding round includes shares of preferred stock and the underlying shares of common stock from converting said stock.
Money in the round came from 11 anonymous investors, according to the SEC filing, with the 1st sale noted on Dec. 1, 2015. The company is looking for an additional $1 million before closing the round.